For decades, Alzheimer's research has chased the visible debris — clearing amyloid plaques and neurofibrillary tangles — yet clinical trials targeting these end-stage aggregates have largely disappointed. A comprehensive review in Ageing Research Reviews reframes the problem: the real therapeutic lever may not be the tangles themselves, but the upstream enzymatic imbalance that produces them.
Tau protein in its normal state is essential for microtubule stabilization and neuronal signaling. The pathological story begins when phosphorylation — the molecular tagging of tau by kinases — runs unchecked due to a breakdown in homeostatic balance between kinase activation and phosphatase activity. Hyperphosphorylated tau detaches from microtubules, self-aggregates into paired helical filaments, and ultimately forms the neurofibrillary tangles long associated with cognitive decline. This review systematically maps the key kinases (notably GSK-3β and CDK5) and phosphatases (particularly PP2A) governing this equilibrium, surveys recent drug-development advances targeting these enzymes, and evaluates tau phosphorylation biomarkers — particularly phospho-tau epitopes in cerebrospinal fluid and plasma — as both diagnostic tools and pharmacodynamic readouts for clinical trials.
The conceptual shift this review crystallizes is clinically significant. GSK-3β inhibitors and PP2A activators have been investigated for years, but interpreting them through a homeostasis lens — restoring balance rather than ablating a single target — offers a more nuanced and arguably more tractable framework. The review's emphasis on precision treatment aligns with growing evidence that different tau phosphorylation signatures may correspond to distinct disease subtypes, potentially explaining why monolithic anti-tau strategies have underperformed. Limitations of the underlying literature remain substantial: most mechanistic data derives from transgenic mouse models and in-vitro systems, human kinase-targeting trials are early-phase, and the causal hierarchy between amyloid pathology and tau dysregulation is still contested. As a synthesis rather than new empirical data, this review is best read as a theoretical roadmap whose clinical validation lies ahead.
